Breaking News, Collaborations & Alliances

Siren Biotechnology, Catalent Partner for Manufacturing of AAV Gene Therapies

Catalent to support the development and manufacturing of Siren Biotechnology’s AAV immuno-gene therapies for cancer.

Author Image

By: Charlie Sternberg

Associate Editor

Siren Biotechnology, pioneers of Universal AAV Immuno-Gene Therapy for Cancer, and Catalent Inc., which was recently acquired by Novo Holdings, have entered a strategic partnership to support the development and manufacturing of Siren Biotechnology’s AAV immuno-gene therapies.   Under the partnership, Catalent will provide process development and cGMP manufacturing of Siren Biotechnology’s adeno-associated viral (AAV) vector-based therapeutic candidates for use in clinical trials. Catalent wil...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters